GlassScriptPhysician profile
Rashadah Jordan
NPI 1275197980
$7,945.41
in general payments reported to CMS, 2019-2025
25 companies · $2,969 in 2025
The $2,969 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $603 · 2022: $1,208 · 2023: $1,234 · 2024: $1,932 · 2025: $2,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,845 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,844.60 |
| Education | $289.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,341.55 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,323.37 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $1,153.52 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $781.31 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $501.97 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $372.64 | 2021-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $368.94 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $366.54 | 2023-2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $320.89 | 2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $215.01 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $205.93 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $130.79 | 2024 | |
| Lundbeck LLC | $127.24 | 2022-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $126.32 | 2024-2025 | Trintellix |
| Corium, LLC | $116.75 | 2023-2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $93.19 | 2024-2025 | Aplenzin |
| Alkermes, INC. | $83.81 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Axsome Therapeutics, INC. | $68.79 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $59.25 | 2023 | |
| Tris Pharma INC | $57.69 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $47.91 | 2022-2024 | Quviviq |
| Owp Pharmaceuticals, INC. | $23.09 | 2023 | Lamotrigine, Subvenite |
| Merck Sharp & Dohme LLC | $21.22 | 2023 | Belsomra |
| Almatica Pharma LLC | $19.86 | 2024 | Loreev Xr |
| Neos Therapeutics, LP | $17.83 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashadah Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.